company background image
ADTX logo

Aditxt NasdaqCM:ADTX Stock Report

Last Price

US$3.37

Market Cap

US$6.6m

7D

-9.7%

1Y

-90.5%

Updated

18 Mar, 2024

Data

Company Financials +

ADTX Stock Overview

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.

ADTX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Aditxt, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aditxt
Historical stock prices
Current Share PriceUS$3.37
52 Week HighUS$76.40
52 Week LowUS$3.27
Beta1.02
1 Month Change-12.01%
3 Month Change-26.42%
1 Year Change-90.48%
3 Year Change-99.95%
5 Year Changen/a
Change since IPO-99.97%

Recent News & Updates

Recent updates

Aditxt gains on regaining compliance with Nasdaq listing requirements

Sep 29

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Sep 13

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Jul 08

Aditxt adds Lauren Chung to board of directors

Jun 18

Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring

Dec 14

We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth

Nov 23
We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth

Shareholder Returns

ADTXUS BiotechsUS Market
7D-9.7%-2.1%-0.1%
1Y-90.5%10.4%28.4%

Return vs Industry: ADTX underperformed the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: ADTX underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is ADTX's price volatile compared to industry and market?
ADTX volatility
ADTX Average Weekly Movement17.8%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ADTX's share price has been volatile over the past 3 months.

Volatility Over Time: ADTX's weekly volatility has decreased from 68% to 18% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201761Amro Albannahttps://www.aditxt.com

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.

Aditxt, Inc. Fundamentals Summary

How do Aditxt's earnings and revenue compare to its market cap?
ADTX fundamental statistics
Market capUS$6.61m
Earnings (TTM)-US$29.73m
Revenue (TTM)US$749.48k

8.8x

P/S Ratio

-0.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADTX income statement (TTM)
RevenueUS$749.48k
Cost of RevenueUS$641.14k
Gross ProfitUS$108.34k
Other ExpensesUS$29.83m
Earnings-US$29.73m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-15.15
Gross Margin14.46%
Net Profit Margin-3,966.15%
Debt/Equity Ratio-98.7%

How did ADTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.